Experimental as well as clinical data do not support the hypothesis that atorvastatin or any other statin affects the antithrombotic potency of clopidogrel.
Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein The PIOSTAT Study
Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction
Web-based resource of cardiovascular physiology concepts that has been written for students, teachers, and health professionals. The contents of this site can be entered by several different routes.
Women and Heart Disease The Role of Diabetes and Hyperglycemia Elizabeth Barrett-Connor, MD; Elsa-Grace V. Giardina, MD; Anselm K. Gitt, MD; Uwe Gudat, MD; Helmut O. Steinberg, MD; Diethelm Tschoepe, MD Arch Intern Med. 2004;164:934-942.
In postmenopausal women with relatively low total fat intake, a greater saturated fat intake is associated with less progression of coronary atherosclerosis, whereas carbohydrate intake is associated with a greater progression.
paradox that a high-fat, high–saturated fat diet is associated with diminished coronary artery disease progression in women with the metabolic syndrome, a condition that is epidemic in the United States. This paradox presents a challenge to differentiat
Surgery does not deal with the basic molecular foundation of disease. It is a mechanical approach to a biologic problem. For those of us who are considered experts in the areas of coronary disease, what an embarrassment to admit that coronary artery disea
The morbidity, mortality, expense and transient benefits of a high technology approach toward the coronary disease epidemic, has failed. It is time to realize that the answer to a faulty lifestyle epidemic is not drugs and technology – it is lifestyle.
Modern cardiology has given up on curing heart disease. Its aggressive interventions-- coronary artery bypass graft, atherectomy, angioplasty, and stenting--do not reduce the frequency of new heart attacks or prolong survival except in small subsets of pa
An unreasonable gap exists between medical enthusiasm devoted to acute interventions and meager efforts devoted to secondary prevention. Rene C. Favaloro, MD, Pioneer of Coronary Artery Bypass Graft Surgery
elective PTCA of totally occluded coronary arteries is feasible but the primary success rate is lower (57%) than that associated with conventional lesions. The long-term clinical results following successful angioplasty are satisfactory (64%), but the inc
Our patient exemplified the challenges involved in a CTO, which included the length of the lesion, the lack of a proximal nipple, the presence of a side branch at the occlusion point, poor visualization of the distal vessel despite contralateral injection
Human resolvin E1 inhibits both the migration of inflammatory cells to sites of inflammation and the turning on of other inflammatory cells. Aspirin-triggered resolivins are made from omega-3 fatty acids by cellular enzymes. COX-2 inhibitors also inhibit
Drug-eluting stents (DES) have gained widespread adoption being implanted in over 6 million patients worldwide demonstrating significant improvements in clinical efficacy combined with comparable safety to bare metal stents.
An investigational drug-eluting stent called Xience, coated with everolimus, led to significantly less late lumen loss after nine months than did the Taxus (paclitaxel-eluting) stent, said researchers here today. March 2007
An investigational bioabsorbable coronary artery stent, in its first human trials, showed acceptable safety, with efficacy better than bare-metal devices but well short of drug-eluting devices, Dutch researchers said here.
Martin Leon, M.D., a leading interventional cardiologist accused of leaking details of a major study weeks before its scheduled release, was barred today from taking part in next year's American College of Cardiology meeting.
An investigational bioabsorbable magnesium coronary stent worked as advertised for several months but led to a higher revascularization rate at one year.
B. George, S. Seals, and I. Aban. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 21 (4):
686-94(August 2014)Anàlisi de supervivència; Introductori; SAS.
S. Deb, P. Austin, J. Tu, D. Ko, C. Mazer, A. Kiss, and S. Fremes. The Canadian journal of cardiology, 32 (2):
259-65(February 2016)Propensity score; CV; Introductori<br/><br/>Taula 1 de ATE/ATT per mètode.
S. Pocock, T. Clayton, and G. Stone. Journal of the American College of Cardiology, 66 (25):
2886-98(December 2015)Disseny; Dissenys adaptatius; Tests d'equivalència; Early stopping; RCT; Introductori; CV<br/><br/>Molts exemples i bons gràfics.
S. Pocock, J. McMurray, and T. Collier. Journal of the American College of Cardiology, 66 (23):
2648-62(December 2015)Disseny; RCT; CV; Introductori; Comparacions múltiples; Composite endpoints; Intention to treat; Anàlisi de subgrups.
